Evidence map›Paper›PMID 28942243›Full record

ArticleNeoplasia (New York, N.Y.)2017

ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity.

Lu Zhang, Yuan Wang, Xiaojie Li, Xin Xia, Na Li, Ruiping He, Hongtao He, Chuanchun Han, Wenzhi Zhao

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Methylation ofAdvanced biomedical research · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.Current treatment options in oncology · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lu ZhangDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China.
Yuan WangDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China.
Xiaojie LiCollege of Stomatology, Dalian Medical University, Dalian 116044, China.
Xin XiaDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China.
Na LiPathology Department of College of Basic Medical Science, Dalian Medical University, Dalian 116044, China.
Ruiping HeDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China.
Hongtao HeDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China.
Chuanchun HanDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China. Electronic address: hanchuanchun@163.com.
Wenzhi ZhaoDepartment of Orthopedics, Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian116027, China. Electronic address: drzhaowenzhi@sina.com.
Dalian Medical University · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance remains a major drawback to osteosarcoma treatment. ZBTB7A, a member of the POK transcription repressor family, was shown to play an important role in tumorigenesis. However, the effect of ZBTB7A on osteosarcoma chemoresistance is completely unknown. In this study, we found that ZBTB7A is increased in cisplatin-resistant osteosarcoma cells and that elevated ZBTB7A inhibits cisplatin-induced apoptosis by repressing LINC00473 expression. Further mechanistic studies revealed that ZBTB7A directly binds to the promoter and suppresses the transcription of LINC00473. Additionally, our data indicate that LINC00473 interacts with the transcript factor C/EBPβ, facilitating its binding to the promoter of IL24, leading to decrease chemoresistance. Thus, these findings indicate that the ZBTB7A-mediated LINC00473-C/EBPβ-IL24 pathway is a promising novel target for overcoming cisplatin resistance in osteosarcoma.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCisplatinDNA-Binding ProteinsDrug Resistance, NeoplasmHumansInterleukin-24InterleukinsOsteosarcomaRNA, Long NoncodingTranscription FactorsCisplatinDNA-Binding ProteinsInterleukin-24InterleukinsLINC00473 RNA, humanRNA, Long NoncodingTranscription FactorsZBTB7A protein, human

Identifiers

PMID28942243
PMCPMC5609875
OpenAlexW2758097371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.